SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. lowered its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,640,445 shares of the company's stock after selling 363,303 shares during the quarter. Brown Advisory Inc. owned 8.68% of SI-BONE worth $51,039,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. raised its holdings in SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock worth $33,341,000 after purchasing an additional 236,167 shares during the last quarter. Geode Capital Management LLC grew its stake in SI-BONE by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock valued at $13,097,000 after acquiring an additional 9,847 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in SI-BONE by 35.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock valued at $11,791,000 after acquiring an additional 220,555 shares in the last quarter. Impax Asset Management Group plc raised its position in SI-BONE by 1.1% during the fourth quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock worth $10,750,000 after acquiring an additional 8,240 shares during the last quarter. Finally, Pier Capital LLC lifted its holdings in shares of SI-BONE by 1.6% in the fourth quarter. Pier Capital LLC now owns 473,123 shares of the company's stock valued at $6,633,000 after purchasing an additional 7,225 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SIBN. Truist Financial upped their target price on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a research note on Tuesday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE has a consensus rating of "Buy" and an average price target of $24.40.

Insiders Place Their Bets

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the transaction, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. The trade was a 1.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the transaction, the insider now directly owns 284,555 shares of the company's stock, valued at approximately $4,026,453.25. The trade was a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,775 shares of company stock worth $95,711 over the last quarter. 3.90% of the stock is owned by corporate insiders.

SI-BONE Trading Up 6.2 %

SIBN stock traded up $1.02 during trading on Wednesday, reaching $17.47. 1,348,246 shares of the stock traded hands, compared to its average volume of 366,828. The business's 50 day moving average price is $14.49 and its 200-day moving average price is $14.73. The firm has a market capitalization of $742.98 million, a PE ratio of -18.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $19.16.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. As a group, sell-side analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.